Apolipoprotein-B mRNA-editing complex 3B could be a new potential therapeutic target in endometriosis.
Humans
Endometriosis
/ genetics
Female
Apoptosis
/ genetics
Cytidine Deaminase
/ genetics
Cell Proliferation
/ genetics
Minor Histocompatibility Antigens
/ genetics
Class I Phosphatidylinositol 3-Kinases
/ genetics
Cell Movement
/ genetics
Adult
Proto-Oncogene Proteins p21(ras)
/ genetics
Gene Knockdown Techniques
Cell Line
Hypoxia-Inducible Factor 1, alpha Subunit
Apolipoprotein-B mRNA-editing complex 3B
Apoptosis
Endometriosis
Potential therapeutic target
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 10 2024
23 10 2024
Historique:
received:
05
08
2024
accepted:
15
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
This study investigated the correlation of Apolipoprotein-B mRNA-editing complex 3B (APOBEC3B) expression with hypoxia inducible factor 1α (HIF-1α), Kirsten rat sarcoma virus (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in endometriosis patients, and the inhibitory effects of APOBEC3B knockdown in a human endometriotic cell line. Here, APOBEC3B, HIF-1α, KRAS, and PIK3CA were examined in patients with and without endometriosis using reverse transcription polymerase chain reaction (RT-PCR). The apoptosis, cell proliferation, invasion, migration, and biological function of APOBEC3B knockdown were explored in 12Z immortalized human endometriotic cell line. We observed APOBEC3B, HIF-1α, KRAS and PIK3CA expressions were significantly higher in endometriosis patients (p < 0.001, p < 0.001, p = 0.029, p = 0.001). Knockdown of APOBEC3B increased apoptosis, which was 28.03% and 22.27% higher than in mock and control siRNA samples, respectively. APOBEC3B knockdown also decreased PIK3CA expression and increased Caspase 8 expression, suggesting a potential role in the regulation of apoptosis. Furthermore, knockdown of APOBEC3B significantly inhibited cell proliferation, invasion, and migration compared to mock and control siRNA. (Cell proliferation: mock: p < 0.001 and control siRNA: p = 0.049. Cell invasion: mock: p < 0.001 and control siRNA: p = 0.029. Cell migration: mock: p = 0.004, and control siRNA: p = 0.014). In conclusion, this study suggests that APOBEC3B may be a new potential therapeutic target for endometriosis.
Identifiants
pubmed: 39443671
doi: 10.1038/s41598-024-76589-2
pii: 10.1038/s41598-024-76589-2
doi:
Substances chimiques
APOBEC3B protein, human
EC 3.5.4.5
Cytidine Deaminase
EC 3.5.4.5
Minor Histocompatibility Antigens
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
KRAS protein, human
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24968Subventions
Organisme : Japan Society for the Promotion of Science
ID : 22K09619
Organisme : Japan Society for the Promotion of Science
ID : 23K15815
Informations de copyright
© 2024. The Author(s).
Références
Zondervan, K. T., Becker, C. M. & Missmer, S. A. Endometriosis. N. Engl. J. Med. 382, 1244–1256. https://doi.org/10.1056/NEJMra1810764 (2020).
doi: 10.1056/NEJMra1810764
pubmed: 32212520
Zhan, L. et al. Hypoxia-inducible factor-1alpha: A promisingtherapeutic target in endometriosis. Biochimie. 123, 130–137. https://doi.org/10.1016/j.biochi.2016.01.006 (2016).
doi: 10.1016/j.biochi.2016.01.006
pubmed: 26898675
Bulun, S. E., Wan, Y. & Matei, D. Epithelial Mutationsin Endometriosis: Link to Ovarian Cancer. Endocrinology. 160, 626–638. https://doi.org/10.1186/s13045-023-01425-510.1210/en.2018-00794 (2019).
doi: 10.1186/s13045-023-01425-510.1210/en.2018-00794
pubmed: 30657901
pmcid: 6382454
Butler, K. & Banday, A. R. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. J. Hematolo. Oncol. 16, 31. https://doi.org/10.1186/s13045-023-01425-510.1210/en.2018-00794 (2023).
doi: 10.1186/s13045-023-01425-510.1210/en.2018-00794
Petljak, M. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature. 607, 799–807. https://doi.org/10.1038/s41586-022-04972-y (2022).
doi: 10.1038/s41586-022-04972-y
pubmed: 35859169
pmcid: 9329121
Ratcliff, J. & Simmonds, P. Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution. Virology. 556, 62–72. https://doi.org/10.1016/j.virol.2020.12.018 (2021).
doi: 10.1016/j.virol.2020.12.018
pubmed: 33545556
Anglesio, M. S. & Yong, P. J. Endometriosis- associated Ovarian Cancers. Clin. Obstet. Gynecol. 60, 711–727. https://doi.org/10.1097/GRF.0000000000000320 (2017).
doi: 10.1097/GRF.0000000000000320
pubmed: 28990985
Hollis, R. L. et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat. Commun. 11, 4995. https://doi.org/10.1038/s41467-020-18819-5 (2020).
doi: 10.1038/s41467-020-18819-5
pubmed: 33020491
pmcid: 7536188
Kvaskoff, M. et al. Endometriosis: a high-risk population for major chronic diseases?. Hum. Reprod. Update. 21, 500–516. https://doi.org/10.1093/humupd/dmv013 (2015).
doi: 10.1093/humupd/dmv013
pubmed: 25765863
pmcid: 4463000
Long, X. et al. APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis. Br. J. Cancer. 128, 2054–2062. https://doi.org/10.1038/s41416-023-02239-5 (2023).
doi: 10.1038/s41416-023-02239-5
pubmed: 36997661
pmcid: 10206171
Revathidevi, S. et al. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis. J. Hum. Genet. 67, 323–329. https://doi.org/10.1038/s10038-021-01003-y (2022).
doi: 10.1038/s10038-021-01003-y
pubmed: 35017684
Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977–983. https://doi.org/10.1038/ng.2701 (2013).
doi: 10.1038/ng.2701
pubmed: 23852168
pmcid: 3902892
Kim, H. et al. Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. Curr. Oncol. 28, 1652–1662. https://doi.org/10.3390/curroncol28030154 (2021).
doi: 10.3390/curroncol28030154
pubmed: 33925044
pmcid: 8161743
Wang, S., Jia, M., He, Z. & Liu, X.-S. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 37, 3924–3936. https://doi.org/10.1038/s41388-018-0245-9 (2018).
doi: 10.1038/s41388-018-0245-9
pubmed: 29695832
pmcid: 6053356
Xia, S. et al. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. Oncoimmunology 10, 1975386. https://doi.org/10.1080/2162402X.2021.1975386 (2021).
doi: 10.1080/2162402X.2021.1975386
pubmed: 34552824
pmcid: 8451457
Zhang, J. et al. The roles of APOBEC3B in gastric cancer. Int. J. Clin. Exp. Pathol. 8, 5089 (2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503075/ .
pubmed: 26191203
pmcid: 4503075
Feng, C. et al. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis. Appl. Immunohistochem. Mol. Morphol. 27, 599–605. https://doi.org/10.1097/PAI.0000000000000695 (2019).
doi: 10.1097/PAI.0000000000000695
pubmed: 30095460
Kosumi, K. et al. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. Med. Oncol. 33, 26. https://doi.org/10.1007/s12032-016-0739-7 (2016).
doi: 10.1007/s12032-016-0739-7
pubmed: 26880326
Rüder, U. et al. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. Histol. Histopathol. 34, 405–417. https://doi.org/10.14670/HH-18-050 (2019).
doi: 10.14670/HH-18-050
pubmed: 30289149
Du, Y. et al. APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study. Cancer Cell Int. 18, 78. https://doi.org/10.1186/s12935-018-0572-5 (2018).
doi: 10.1186/s12935-018-0572-5
pubmed: 29853799
pmcid: 5975489
Mao, Y. et al. APOBEC3B expression and its prognostic potential in breast cancer. Oncol. Lett. 19, 3205–3214. https://doi.org/10.3892/ol.2020.11433 (2020).
doi: 10.3892/ol.2020.11433
pubmed: 32256817
pmcid: 7074638
Zhang, S. .-Q. et al. APOBEC3B expression has prognostic significance in cervical cancer. Int. J. Clin. Exp. Pathol. 16, 48–56 (2023) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076974/ .
pubmed: 37033395
pmcid: 10076974
Anglesio, M. S. et al. Cancer-Associated Mutations in Endometriosis without Cancer. N. Engl. J. Med. 376, 1835–1848. https://doi.org/10.1056/NEJMoa1614814 (2017).
doi: 10.1056/NEJMoa1614814
pubmed: 28489996
pmcid: 5555376
Hossain, M. M. et al. Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations for Understanding the Underlying Biology and Molecular Pathogenesis. Cancers. 13, 3174. https://doi.org/10.3390/cancers13133174 (2021).
doi: 10.3390/cancers13133174
pubmed: 34202354
pmcid: 8269352
Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7, 1833–1841. https://doi.org/10.1016/j.celrep.2014.05.012 (2014).
doi: 10.1016/j.celrep.2014.05.012
pubmed: 24910434
Bader, S. B. et al. Replication catastrophe induced by cyclic hypoxia leads to increased APOBEC3B activity. Nucleic Acids Res. 49, 7492–7506. https://doi.org/10.1093/nar/gkab551 (2021).
doi: 10.1093/nar/gkab551
pubmed: 34197599
pmcid: 8287932
Leonard, B. et al. The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res. 75, 4538–4547. https://doi.org/10.1158/0008-5472.CAN-15-2171-T (2015).
doi: 10.1158/0008-5472.CAN-15-2171-T
pubmed: 26420215
pmcid: 4631676
Liu, W. et al. Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional polymorphisms on biliary tract cancer risk. Int. J. Cancer. 150, 1825–1837. https://doi.org/10.1002/ijc.33930 (2022).
doi: 10.1002/ijc.33930
pubmed: 35020946
Jin, Z., Han, Y.-X. & Han, X.-R. The role of APOBEC3B in chondrosarcoma. Oncol. Rep. 32, 1867–1872. https://doi.org/10.3892/or.2014.3437 (2014).
doi: 10.3892/or.2014.3437
pubmed: 25176183
Wei, Z. et al. APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway. Front. Oncol. 12, 864889. https://doi.org/10.3389/fonc.2022.864889 (2022).
doi: 10.3389/fonc.2022.864889
pubmed: 36249021
pmcid: 9556651
Ma, W. et al. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Mol. Carcinog. 58, 643–653. https://doi.org/10.1002/mc.22956 (2019).
doi: 10.1002/mc.22956
pubmed: 30575099
Zeitvogel, A., Baumann, R. & Starzinski-Powitz, A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am. J. Pathol. 159, 1839–1852. https://doi.org/10.1016/S0002-9440(10)63030-1 (2001).
doi: 10.1016/S0002-9440(10)63030-1
pubmed: 11696444
pmcid: 1867070
Ruiz, A. et al. Pharmacological blockage of the CXCR4-CXCL12 axis in endometriosis leads to contrasting effects in proliferation, migration, and invasion. Biol. Reprod. 98, 4–14. https://doi.org/10.1093/biolre/iox152 (2018).
doi: 10.1093/biolre/iox152
pubmed: 29161347
Chelariu-Raicu, A. et al. Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype. Fertil. Steril. 106, 378–385. https://doi.org/10.1016/j.fertnstert.2016.03.032 (2016).
doi: 10.1016/j.fertnstert.2016.03.032
pubmed: 27041028